Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

Core Viewpoint - Bayer has initiated its Phase III study SUNFLOWER to evaluate the efficacy and safety of the 52mg levonorgestrel-releasing intrauterine system Mirena® for treating nonatypical endometrial hyperplasia (NAEH) in women [1] Group 1 - The study focuses on nonatypical endometrial hyperplasia, which is characterized by abnormal thickening of the endometrial lining due to hormonal imbalance [1] - NAEH is classified as nonatypical because the cells do not exhibit atypical features [1]